|
The result was announced after market hours yesterday, 9 May 2017.
Meanwhile, the S&P BSE Sensex was up 263.29 points, or 0.88%, to 30,196.54. The S&P BSE Small-Cap index was up 130.87 points, or 0.84% to 15,675.50
On the BSE, 7,662 shares were traded on the counter so far as against the average daily volumes of 6,031 shares in the past one quarter. The stock had hit a high of Rs 968 and a low of Rs 945 so far during the day. The stock had hit a 52-week high of Rs 1,151 on 9 May 2016 and a 52-week low of Rs 909 on 1 March 2017.
The stock had outperformed the market over the past one month till 9 May 2017, rising 2.76% compared with 1.21% rise in the Sensex. The scrip, however, underperformed the market in past one quarter, gaining 5.09% as against Sensex's 5.81% rise.
The small-cap company has equity capital of Rs 5 crore. Face value per share is Rs 2.
AstraZeneca Pharma India's total income dropped 26.66% to Rs 118.01 crore in Q4 March 2017 over Q4 March 2016.
AstraZeneca Pharma India is engaged in the development and commercialization of medicines for core areas of healthcare, including cardiovascular/metabolic disease, cancer and respiratory, inflammatory and autoimmune disease. AstraZeneca Pharmaceuticals AB holds 75% stake in AstraZeneca Pharma India (as per the shareholding pattern as on 31 March 2017).
|